Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients

Cancer Research and Treatment - South Korea
doi 10.4143/crt.2016.135
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Korean Cancer Association

Related search

Germline BRCA1 and BRCA2 Deleterious Mutations and Variants of Unknown Clinical Significance Associated With Breast/Ovarian Cancer: A Report From North India

Cancer Management and Research
Oncology
2018English

BRCA1 and BRCA2 Mutations and Clinical Interpretation in 398 Ovarian Cancer Patients: Comparison With Breast Cancer Variants in a Similar Population

Human Genomics
Molecular MedicineDrug DiscoveryGeneticsMolecular Biology
2018English

Sensitivity of BRCA1/2 Mutation Testing in 466 Breast/Ovarian Cancer Families

Journal of Medical Genetics
Genetics
2003English

Performance of BRCA1/ 2 Mutation Prediction Models in Male Breast Cancer Patients

Clinical Genetics
Genetics
2017English

Genetic and Histopathologic Evaluation ofBRCA1andBRCA2DNA Sequence Variants of Unknown Clinical Significance

Cancer Research
Cancer ResearchOncology
2006English

Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer According to Tumorigenicity in Patient-Derived Xenograft Models

Cancer Research and Treatment
Cancer ResearchOncology
2018English

Pharmacological Ascorbate Induces ‘BRCAness’ and Enhances the Effects of Poly(ADP‑Ribose) Polymerase Inhibitors Against BRCA1/2 Wild‑type Ovarian Cancer

Oncology Letters
Cancer ResearchOncology
2020English

Pre-Test Prediction Models of BRCA1 or BRCA2 Mutation in Breast/Ovarian Families Attending Familial Cancer Clinics

Journal of Medical Genetics
Genetics
2003English

Analysis of Clinical Characteristics of Breast Cancer Patients With the Japanese Founder Mutation BRCA1 L63X

Oncotarget
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy